InnoSer ’s Post

Excited to share our viewpoint published in JAMA Oncology Vivek Subbiah, MD and I delve into leveraging modern clinical trial tools to enhance access to precision oncology clinical trials. While master protocols and basket trials have revolutionized how these trials are conducted, they fall short in improving trial access. This leads to significant enrollment challenges, affecting representation and even delays. We discuss how modern, decentralized, trial methods offer promising solutions to enhance trial access. #PrecisionOncology #clinicaltrials

Just published! A great piece from JAMA Oncology. Science 37's Dr. Shaalan Beg and Dr. Vivek Subbiah from Sarah Cannon Research Institute delve into how modern clinical trial tools enhance access to precision oncology research. Read it here: https://lnkd.in/ehSqxu-6 #clinicalresearch #clinicaltrials #precisiononcology #oncologyresearch #decentralizedtrials

What happens when a second-generation product has been developed since the introduction of the biosimilar medicine? In the case oncology, it can leave the original molecule and its biosimilar medicines with a potentially smaller market. For example, perceived improved benefits to breast cancer patients means that the new subcutaneous form of trastuzumab has rapidly captured a substantial share of this market segment in Europe. Read more about Assessing the Biosimilar Void by downloading the report: https://bit.ly/46eXqLQ. #Biosimilars #GlobalMedicine #CancerDrugs

Choosing the RIGHT model for your preclinical Immuno-Oncology and Oncology studies is crucial to accelerating your research. Download our Quick Guide comparing Syngeneic & Humanized Mouse Models and learn how to weigh the benefits and challenges you face when working with these models for oncology research. Learn More: https://hubs.li/Q02dkSqj0 #OncologyResearch #CancerResearch #ImmunoOncology #Humanized #Syngeneic

In case you missed it… click here to view the AACR 2023 poster entitled “Inhibition of murine myeloid suppressor cells increases CD8 T cell activation in vitro” presented by Labcorp Discovery Research Associate Anita J. Zaitouna. With more than 6,000 discovery oncology studies completed, we have amassed extensive experience and deep insights to inform oncology research and enable quick, confident decisions about life-saving compounds. #CRO #discovery #oncology

We were thrilled today to present at the American Society of Clinical Oncology (ASCO) Annual Meeting. Two poster presentations spotlighted clinical trial data for Black Diamond’s #EGFR inhibitor BDTX-1535 in patients with recurrent #glioblastoma (GBM). These data were from a Phase 1 dose-escalation trial and a “window of opportunity” (Phase 0/1 “Trigger”) Investigator Sponsored Trial at the Ivy Brain Tumor Center.   Results demonstrated a favorable safety and tolerability profile and encouraging anti-tumor activity and duration of treatment. BDTX-1535 was also shown to achieve clinically meaningful drug levels in brain tumor tissue. Read more: https://lnkd.in/epsPKu_c View the posters here: https://lnkd.in/e3JeikQf   #ASCO2024 #GBM #oncology #biotech #healthcare #innovation

The phase II GMMG-CONCEPT trial showcases the Isa-KRD combination (isatuximab, carfilzomib, lenalidomide, and dexamethasone) as a potent initial treatment option for newly diagnosed high-risk multiple myeloma, achieving deep remissions. This regimen sets the stage for further comparison with treatments like D-RVCD (daratumumab, cyclophosphamide, bortezomib, lenalidomide, dexamethasone) and Dara-KRD (daratumumab, carfilzomib, lenalidomide, dexamethasone) in future research. The study was selected by Dr. Erika Lerch, one of the Oncology Compass Scientific Leaders, and can be found here: https://lnkd.in/da9Rt7gt #multiplemyeloma #oncology

Endpoints in malignant hematology studies differ significantly from those used for solid tumors. In this white paper, Christopher Morley and Sari Heitner Enschede, MD consider the most effective investigational agents for blood-based cancers. Download now. https://bit.ly/48xpIlR #oncology #hematology #biotech #ClinicalTrials #diversity

Interested to hear the latest in #PrecisionOncology? Hear from Dr. Kyle Strickland and Dr. Rebecca Previs as they discuss the different components of liquid biopsy and current technologies used to isolate circulating tumor cells (CTCs) and cell-free DNA (cfDNA). In this webinar, you will learn the potential clinical implications of liquid biopsies on molecular profiling of tumors for therapy selection, early detection of cancer, drug response and therapy resistance. Watch the video to learn more.

ADCs: Transforming Oncology Drug Delivery Check out the latest article by Kenneth Barr, Ph.D. and Jayashree (Jay) Aiyar on the exciting potential of Antibody-Drug Conjugates (ADCs) in oncology. ADCs offer a compelling opportunity to deliver crucial, targeted cancer treatments, enhancing efficacy and reducing side effects. Dive into how these innovative therapies are shaping the future of oncology medications. To read the full article, visit 👉 https://lnkd.in/dHne2hxD #Oncology #ADCs #CancerTreatment #PharmaInnovation #TargetedTherapies